Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche will combine Anadys' experimental non-nucleoside polymerase inhibitor with its own protease inhibitor and nucleoside in the effort to establish an all-oral combination therapy for hepatitis C.